Treatment considerations for patients with pemphigus during the COVID-19 pandemic

Shakshouk, Hadir; Daneshpazhooh, Maryam; Murrell, Dédée F.; Lehman, Julia S.

doi:10.1016/j.jaad.2020.04.005

Cited by 55 publications

(95 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These unconventional clinical settings led to increased concern both in patients treated with immunomodulatory, immunosuppressive or biologic drugs and in prescribing physicians. Several reports have been published to alleviate this concern in treatment of patients with psoriasis, atopic dermatitis and pemphigus [3][4][5] . Considering the lack of information and growing demand on the treatment of patients with common dermatoallergic conditions, a similar attempt has been made by the members of Dermatoallergy Working Group of the Turkish Society of Dermatology.…”

Section: To the Editormentioning

confidence: 99%

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Salman¹,

Alper²,

Atakan³

et al. 2020

TURKDERM

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Salman¹,

Alper²,

Atakan³

et al. 2020

TURKDERM

View full text Add to dashboard Cite

“…Atopic dermatitis patients who demonstrate elevated risk of respiratory comorbidities were advised by the European Academy of Dermatology and Venereology ( EADV ) task force on atopic dermatitis not to modify by themselves previously stable immune‐modulating or immunosuppressive therapies because of increased risk of relapses 13 . Patients with autoimmune bullous dermatoses, especially those suffering from pemphigus and mucous membrane pemphigoid, were informed by the respective AIBD task force on the effects of systemic corticosteroids, steroid‐sparing agents, rituximab, and other treatment options during the COVID‐19 pandemic 14–16 . Patients with connective tissue diseases on disease‐modifying antirheumatic drugs, biologics, or other immunosuppressive medications were advised to consult their rheumatologist and stop these drugs during an infection, while noninfected patients are required to continue their medication during the epidemic 17,18 .…”

Section: Expert Recommendations and Patient Information During Covid‐19mentioning

confidence: 99%

Covid‐19 pandemic and the skin

Drenovska¹,

Schmidt

Vassileva³

2020

Int J Dermatology

View full text Add to dashboard Cite

In the beginning of the COVID-19 outbreak, skin manifestations, if present, were not paid enough attention. Then, the focus moved toward the impact of the prolonged use of personal protective measures in both healthcare workers and patients. In the meantime, attention is increasingly paid to dermatology as a result of the concern for certain groups of dermatologic patients, including those whose condition may worsen by the thorough disinfection measures and those treated with immunosuppressants or immunomodulators. Following patients with psoriasis on biological therapy, as well as other inflammatory and autoimmune cutaneous disorders such as atopic dermatitis, pemphigus, pemphigoid diseases, and skin cancer provoked the interest of dermatologists. Finally, an intriguing question to the dermatologic society was whether skin changes during COVID-19 infection exist and what could be their diagnostic or prognostic value. Here, we summarize skin conditions during the COVID-19 pandemic, patient information, and expert recommendations and give an overview about the registries launched to document skin changes during COVID-19, as well as details about certain patient groups infected with SARS-CoV-2, for example, psoriasis, atopic dermatitis, and autoimmune bullous diseases.

show abstract

“…30 There are concerns especially regarding the long-term immunosuppressive effect of rituximab used for treatment of pemphigus. 34 The initiation of rituximab in patients with autoimmune bullous disease must be weighed against the risks of conventional immunomodulatory regimens on an individual basis. 35 To reduce the risk of infection routine face-to-face appointments could be delayed if they are not urgently needed or substituted by teledermatology.…”

mentioning

confidence: 99%

Cutaneous autoimmune diseases during COVID‐19 pandemic

Günther

Aschoff

Beissert

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Cutaneous autoimmune diseases during COVID-19 pandemic Editor The pandemic of infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing the atypical pneumonia coronavirus disease 19 (COVID-2019) has become a global health emergency. In parallel with the spread of the infection, there is new information on cutaneous involvement reminiscent to autoimmune diseases and concerns about the risk of disease 15 Pityriasis rosea Mild 14

show abstract

Treatment considerations for patients with pemphigus during the COVID-19 pandemic

Cited by 55 publications

References 5 publications

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

Covid‐19 pandemic and the skin

Cutaneous autoimmune diseases during COVID‐19 pandemic

Contact Info

Product

Resources

About